Tandem Diabetes Care Inc (NASDAQ:TNDM) Expected to Post Earnings of -$0.23 Per Share

Equities research analysts expect Tandem Diabetes Care Inc (NASDAQ:TNDM) to announce earnings of ($0.23) per share for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Tandem Diabetes Care’s earnings. The lowest EPS estimate is ($0.42) and the highest is ($0.15). Tandem Diabetes Care posted earnings of ($0.34) per share during the same quarter last year, which would indicate a positive year over year growth rate of 32.4%. The company is scheduled to issue its next quarterly earnings report on Monday, July 29th.

On average, analysts expect that Tandem Diabetes Care will report full-year earnings of ($0.81) per share for the current fiscal year, with EPS estimates ranging from ($1.42) to ($0.33). For the next year, analysts forecast that the business will report earnings of ($0.28) per share, with EPS estimates ranging from ($0.59) to $0.37. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Tandem Diabetes Care.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Tuesday, April 30th. The medical device company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.10). Tandem Diabetes Care had a negative net margin of 50.73% and a negative return on equity of 40.76%. The business had revenue of $66.00 million for the quarter, compared to analysts’ expectations of $47.55 million. During the same quarter in the previous year, the firm earned ($1.82) EPS. Tandem Diabetes Care’s revenue was up 141.9% compared to the same quarter last year.



A number of research firms recently issued reports on TNDM. Craig Hallum boosted their price objective on 1-800-Flowers.Com from $26.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Oppenheimer boosted their price objective on Paycom Software from $175.00 to $220.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. BidaskClub cut Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, June 26th. Stifel Nicolaus boosted their price objective on Zendesk from $75.00 to $83.00 and gave the company a “hold” rating in a report on Wednesday, May 1st. Finally, Lake Street Capital restated a “buy” rating on shares of Tandem Diabetes Care in a report on Monday, June 17th. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $68.13.

TNDM traded up $0.66 during trading hours on Tuesday, reaching $64.62. 932,810 shares of the company’s stock traded hands, compared to its average volume of 982,592. The company’s 50-day moving average price is $65.80. Tandem Diabetes Care has a 52-week low of $24.03 and a 52-week high of $74.81. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.43 and a quick ratio of 2.13. The firm has a market capitalization of $3.75 billion, a price-to-earnings ratio of -25.34 and a beta of 0.41.

In other Tandem Diabetes Care news, Director Dick Allen sold 17,000 shares of Tandem Diabetes Care stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $61.34, for a total transaction of $1,042,780.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David B. Berger sold 2,000 shares of Tandem Diabetes Care stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $63.09, for a total value of $126,180.00. Following the sale, the executive vice president now directly owns 3,765 shares of the company’s stock, valued at $237,533.85. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 105,066 shares of company stock valued at $7,136,287. 6.90% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of TNDM. Nisa Investment Advisors LLC raised its position in shares of Tandem Diabetes Care by 53.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 460 shares of the medical device company’s stock worth $30,000 after acquiring an additional 160 shares in the last quarter. Bremer Bank National Association bought a new position in shares of Tandem Diabetes Care in the 1st quarter worth $31,000. PNC Financial Services Group Inc. bought a new position in shares of Tandem Diabetes Care in the 4th quarter worth $44,000. Advisor Group Inc. raised its position in shares of Tandem Diabetes Care by 38.2% in the 4th quarter. Advisor Group Inc. now owns 2,351 shares of the medical device company’s stock worth $89,000 after acquiring an additional 650 shares in the last quarter. Finally, Rockefeller Capital Management L.P. bought a new position in shares of Tandem Diabetes Care in the 1st quarter worth $122,000. 80.44% of the stock is owned by institutional investors and hedge funds.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Article: Liquidity

Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.